Peripheral Nervous System Diseases

The grounding does not support a single unified cause for peripheral nervous system diseases as a category. It does identify chemotherapy-induced peripheral neuropathy as one specific cause-related subtype within this group, arising in the context of cancer treatment.

The grounding supports several mechanisms relevant to peripheral nerve disease, including axonal degeneration and Wallerian degeneration, in which NAD+ metabolism is implicated in axonal self-destruction. It also describes peripheral sensitization and central sensitization as mechanisms in neuropathic pain, and notes that diabetes-related peripheral neuropathy is associated with neuroinflammation, glial cell alterations, oxidative stress, and impaired vascular function.

The grounding does not support broad risk factors for all peripheral nervous system diseases as a category. It does indicate that diabetes is associated with peripheral neuropathy, and that exposure to chemotherapy is a risk context for chemotherapy-induced peripheral neuropathy.

The grounding supports treatment discussion mainly at the class or modality level for chemotherapy-induced peripheral neuropathy. It indicates that no agents are recommended for prevention of CIPN, that acetyl-L-carnitine should be discouraged for prevention, and that management is based on evidence review of drug therapy and other supportive approaches rather than a single established preventive medication.